Company / EPS (Diluted)
Royalty Pharma plc EPS (Diluted) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$2.53
FY2025
5-year range
$0.10 / $2.53
FY2021-FY2025
Trend
+2430.0%
vs FY2024
Sector context
#20 of 204
Health Care
What the data says
EPS (Diluted) changed +2430% YoY in FY2025, a notable deviation from the 5-year average annual change of +470%.
Based on SEC 10-K filings.
2.53 in FY2025 with a 5-year CAGR of +13.9%. Top quartile in the Health Care sector.
Improved from $1.49 to $2.53 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +24.2%
- 5-Year CAGR
- +13.9%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 204This company $2.53 Sector average -$0.98
▼
+358.3% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 2430.0% year-over-year.
- Ranks #20 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- Strong profit margin: 38.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.53 | +2430.0% |
| FY2024 | $0.10 | -93.3% |
| FY2023 | $1.49 | +12.9% |
| FY2022 | $1.32 | +0.0% |
| FY2021 | $1.32 | +0.0% |
| FY2020 | $1.32 | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026